Malignant Glioma — Trials

Malignant Glioma — Trials · CancerIndex

Clinical trials

Registered studies

2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 589
Recruiting: 314
Ph III recruiting: 16
Growth YoY: +38.9%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (325)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06639607	PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma(PRiME II)	suspended	Phase 1 / Phase 2	68	Washington University School of MedicineOTHER	1	Sep 11, 2026	clinicaltrials
NCT06329570	Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)	suspended	Phase 1 / Phase 2	10	NaviFUS CorporationINDUSTRY